Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
-
Bayern beat Freiburg to reclaim top spot after Kompany illness
-
Monaco hold Lille as Rennes go top of Ligue 1
-
Nigeria widens hunt for possible Ebola cases
-
Thousands gather in Prague to protest licence fee plans
-
Liverpool star Isak back to his best says Iraola
-
Pease spins to floor gold as US tops gymnastics medal table
-
Lula supporters cross fingers in Rio, a Bolsonaro bastion
-
Marchant back in England training squad ahead of Nations Championship fixtures
-
Flights resume at Riyadh airport as Houthis attack Saudi Arabia
-
French skater Siao Him Fa soars to victory in season-opener at home
-
High-flying Betis held at Celta Vigo
-
Embattled Albanian PM vows fines for violent protesters
-
Shadab ton stuns England as Pakistan reach tri-series final
-
Steelers top Saints in NFL's first regular-season game in Paris
-
'With you': Opposition leader Machado returns to Venezuela
-
Carrick unsure over Man Utd future after Bournemouth loss
-
Carrick on the brink as Man Utd misery mounts, Isak stars for Liverpool
-
2027 Dakar Rally to be moved from Saudi Arabia
-
Monaco hold Lille as both move to top of Ligue 1
-
Man Utd battered by Bournemouth to leave Carrick on the brink
-
Isak extends hot streak as Liverpool sink Brighton
-
Storms batter Europe hitting power supplies, flights and phones
-
Brazil chooses between Lula and Bolsonaro in nail-biter vote
-
Inter rally late to down Fiorentina and regain Serie A lead
-
J&K Bank raises accident cover for government employees to ₹1 crore
-
Doha opens ninth World Investment Forum focused on future investment
-
UDST opens Fall 2027 admissions to students in Qatar and abroad
-
Kuwait public works minister and UK ambassador discuss closer cooperation
-
Le Pen begins presidential campaign after violent protests across France
-
Historic Ramallah olive press joins modern production with local tradition
-
Adan Hospital launches catheter-based tricuspid valve replacement programme
-
Hebron operation forces 373 Palestinian families from their homes
-
KIB Group nine-month profit rises 30% to KD 26.6 million
-
Kuwait legal department reviews new commercial concealment law
-
John Catlin wins Hong Kong Open and secures first Masters invitation
-
Ladakh declared India’s first fully organic union territory
-
Poland’s WB Group plans $100 million India investment for drone production
-
IRDAI gives stakeholders until October 31 to comment on distribution reforms
-
Insurance deductibles and no-claim bonuses require a careful claims decision
-
Bay cyclone forecast to strike Andhra-Yanam coast at very severe strength
-
Credit-card shortcuts can turn impulse spending into lasting debt
-
Technical outlook diverges for Bharti Airtel, PFC, REC and Alkyl Amines
-
Chicago Fire rally past Atlanta United 3-2 to hold fourth place
-
Pinheiro Braathen wins Soelden giant slalom
-
Serbia on track for high turnout as students challenge ruling party
-
Man Utd's Fernandes dropped by Carrick after Como outburst
-
Pakistan keep England to 241 despite Duckett ton
-
England great Anderson's future unclear after Lancashire exit
-
Ukraine war divides Bulgaria as voters elect president
-
Demonstrators wounded as Portugal police clear housing protest camps
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / New to The Street's longtime featured biotechnology client, Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), highlighted a potentially transformative regulatory development for companies developing therapies targeting Clostridioides difficile infection (CDI), as the U.S. Food and Drug Administration finalized updated guidance that may significantly streamline the path toward approval for new CDI antibiotics.
The FDA's newly finalized guidance, titled "Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention," outlines updated recommendations for the clinical development of CDI therapies. Most notably, the guidance indicates that under certain circumstances, FDA approval may now be supported by a single pivotal clinical trial combined with confirmatory evidence, representing a major shift from the traditional requirement of two successful Phase 3 studies.
The finalized guidance has the potential to accelerate development timelines and reduce the complexity of bringing urgently needed new antibiotic therapies to market for patients suffering from CDI, a serious bacterial infection that remains a major healthcare challenge globally.
Acurx Pharmaceuticals is currently advancing ibezapolstat, its first-in-class DNA polymerase IIIC inhibitor antibiotic candidate for the treatment of CDI. The company's program is considered Phase 3-ready, with prior alignment discussions already completed with the European Medicines Agency (EMA).
The updated FDA guidance may further support the company's efforts to efficiently advance ibezapolstat through the regulatory pathway as Acurx continues engaging with regulators regarding its pivotal development strategy.
Acurx Pharmaceuticals continues to position itself as an innovative leader in antimicrobial resistance (AMR) and next-generation antibiotic development, targeting one of the most challenging infection categories facing healthcare systems worldwide.
New to The Street has featured Acurx Pharmaceuticals across its sponsored programming television broadcasts on Bloomberg Television and Fox Business, digital media platforms, earned media distribution, and outdoor billboard campaigns as part of its ongoing long-form executive media partnership.
To learn more about Acurx Pharmaceuticals and ibezapolstat, visit:
Acurx Pharmaceuticals Website
About New to The Street
New to The Street is one of the longest-running U.S. and international sponsored television brands, broadcasting as sponsored programming on Bloomberg Television and Fox Business. The platform features public and private companies through long-form interviews, earned media, commercial campaigns, outdoor billboard advertising, and one of the largest financial television YouTube channels in the world with over 4.7 million subscribers.
About NewsOut
NewsOut is a next-generation media and video press release platform combining television-style production, executive storytelling, social distribution, and digital amplification to help public and private companies increase visibility across financial media, YouTube, and investor-focused audiences worldwide. The NewsOut YouTube Channel has surpassed 854,000 subscribers and continues to rapidly expand its reach across investor, business, and financial audiences globally.
Contact: Monica Brennan [email protected]
SOURCE: New to The Street
View the original press release on ACCESS Newswire
P.Martin--AMWN
